Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251261 · ClinicalTrials.gov registry record
Detection of Cytomegalovirus Virus in Neonates
A clinical trial of CMV, sponsored by Meridian Bioscience.
- Completed
- Registry status
- 1,615
- Enrollment target
- 5
- Study locations
NCT03251261 is a study of CMV that has completed, run by Meridian Bioscience. The registered enrollment target is 1,615 participants, above the 132-participant average among 7 other CMV trials with a reported enrollment target (1123% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT03251261, a study of CMV, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- 1,615 participants
- Enrollment target
- 5
- Study locations
Study Summary
To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
Conditions Studied
Interventions
- DEVICE illumigene CMV assay, illumipro-10
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
Utah
- University of Utah - Salt Lake City
New South Wales
- The Prince of Wales Hospital - Randwick
British Coloumbia
- British Columbia Children's Hospital / British Columbia Women's Hospital - Vancouver
Province of Bologna
- Ospedale Sant'Orsola - Via Massarenti 19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,615 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2018-03-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03251261
The ClinicalTrials.gov registry entry for NCT03251261 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,615 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 132-participant average among 7 other CMV trials with a reported enrollment target (1123% higher). The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CMV appearing as the primary indexed condition, and to 1 intervention - of which illumigene CMV assay, illumipro-10 is the first listed.
NCT03251261 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Utah, New South Wales.
Frequently Asked Questions
What is clinical trial NCT03251261 about?
NCT03251261 is a clinical study titled "Detection of Cytomegalovirus Virus in Neonates". To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
What is the current status of trial NCT03251261?
This trial is currently completed. The enrollment target is 1,615 participants. The study started on 2017-08-02. Estimated completion is 2018-03-05.
What conditions does trial NCT03251261 study?
This clinical trial studies the following conditions: CMV.
What interventions are being tested in trial NCT03251261?
The interventions under investigation include: illumigene CMV assay, illumipro-10 (DEVICE).
Who is sponsoring clinical trial NCT03251261?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03251261 being conducted?
This trial has 5 study locations across Alabama, Utah, New South Wales, British Coloumbia, Province of Bologna. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CMV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
RECRUITING
-
CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
RECRUITING · Phase 2
-
CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients
RECRUITING · Phase 1
-
Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
ACTIVE NOT RECRUITING · Phase 2
-
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 3
-
CMV T Cell Immunity in Pediatric Solid Organ Transplant Recipients
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.